About the Authors
- Daan T. Geraets, Leen-Jan van Doorn, Bernhard Kleter, Wim G. V. Quint
- DDL Diagnostic Laboratory, Rijswijk, The Netherlands
- Brigitte Colau
- GlaxoSmithKline Vaccines, Rixensart, Belgium
- Diane M. Harper
- Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire, United States of America
The authors have read the journal's policy and have the following conflicts: All authors declared that the following interests are relevant to the submitted work. DG and BK have declared no conflicts of interest. LJvD and WQ are employees and shareholders of DDL Diagnostic Laboratory. BC is an employee of the GlaxoSmithKline group of companies and holds shares in GSK. The institutions at which DH has conducted HPV vaccine trials have received funding to support clinical trials on the vaccines discussed herein from Merck and Co and GlaxoSmithKline. DH has also received honoraria for speaking and for participation on advisory boards from Merck and Co. and GlaxoSmithKline. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: DG LJvD BK BC DH WQ. Performed the experiments: DG LJvD BK. Analyzed the data: DG LJvD BC WQ. Contributed reagents/materials/analysis tools: BC DH WQ. Wrote the manuscript: DG LJvD BK BC DH WQ.